The Treatment

May 2019

Investing in the European life sciences sector, in particular pharmaceuticals, biotechnology and medical devices, can unlock a substantial portion of the global life sciences market.

IQVIA Institute reports that medicine spending in the top five European countries alone was US$177.5bn (15%) of the global amount in 2018.

The European medicines market as a whole is second only to North America and boasts growth in 2018 of 3.9%, representing considerable opportunities for investment.

The Treatment is designed to provide a high level overview of some of the most important issues to consider for any life sciences company seeking these opportunities by coming to Europe.

If you have any questions on this article or would like to propose a subject to be addressed by Synapse please contact us.